CD44 and neoplasm: These include increased shift toward M2 protumoral phenotype in tumor-associated macrophages [16], a reduced granzyme B-producing CD3+CD8+GzmB+ T cells [41], increased circulating VEGF [42] and increased cancer stem cells markers on Oct4+ and CD44+CD133+ expressing TC1 tumor cells [41].